THAR vs. NRSN, FLGC, TRAW, EDSA, RDHL, AKTX, IMNN, PIRS, KPRX, and ELAB
Should you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), Traws Pharma (TRAW), Edesa Biotech (EDSA), RedHill Biopharma (RDHL), Akari Therapeutics (AKTX), Imunon (IMNN), Pieris Pharmaceuticals (PIRS), Kiora Pharmaceuticals (KPRX), and Elevai Labs (ELAB). These companies are all part of the "pharmaceutical preparations" industry.
Tharimmune (NASDAQ:THAR) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation.
1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 2.4% of Tharimmune shares are owned by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Tharimmune had 2 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 5 mentions for Tharimmune and 3 mentions for NeuroSense Therapeutics. Tharimmune's average media sentiment score of 0.96 beat NeuroSense Therapeutics' score of 0.62 indicating that Tharimmune is being referred to more favorably in the media.
Tharimmune has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500.
Tharimmune's return on equity of -169.23% beat NeuroSense Therapeutics' return on equity.
NeuroSense Therapeutics received 2 more outperform votes than Tharimmune when rated by MarketBeat users.
Summary
Tharimmune beats NeuroSense Therapeutics on 6 of the 10 factors compared between the two stocks.
Get Tharimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tharimmune Competitors List
Related Companies and Tools
